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Abstract
 Background—Among patients receiving hemodialysis, abnormalities in calcium regulation 
have been linked to an increased risk of cardiovascular events. Cinacalcet lowers serum calcium 
concentrations through its effect on parathyroid hormone secretion and has been hypothesized to 
reduce the risk of cardiovascular events. In observational cohort studies, prescriptions of low 
dialysate calcium concentration and larger observed serum–dialysate calcium gradients have been 
associated with higher risks of in-dialysis facility or peri-dialytic sudden cardiac arrest. We 
performed this study to examine risks associated with dialysate calcium and serum-dialysate 
gradients among participants in the Evaluation of Cinacalcet Hydrochloride Therapy to Lower 
Cardiovascular Events (EVOLVE) trial.
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 Methods—In EVOLVE, 3883 hemodialysis patients were randomized 1:1 to cinacalcet or 
placebo. Dialysate calcium was administered at the discretion of treating physicians. We examined 
whether baseline dialysate calcium concentration or the serum–dialysate calcium gradient 
modified the effect of cinacalcet on the following adjudicated endpoints: 1) primary composite 
endpoint (death or first non-fatal myocardial infarction, hospitalization for unstable angina, heart 
failure or peripheral vascular event); 2) cardiovascular death; and 3) sudden death.
 Results—In EVOLVE, use of higher dialysate calcium concentrations was more prevalent in 
Europe and Latin America compared to North America. There was a significant fall in serum 
calcium concentration in the cinacalcet group; dialysate calcium concentrations were changed 
infrequently in both groups. There was no association between baseline dialysate calcium 
concentration or serum–dialysate calcium gradient and the endpoints examined. Neither the 
baseline dialysate calcium nor the serum–dialysate calcium gradient significantly modified the 
effects of cinacalcet on the outcomes examined.
 Conclusions—The effects of cinacalcet on cardiovascular death and major cardiovascular 
events are not altered by the dialysate calcium prescription and serum-dialysate calcium gradient.
 INTRODUCTION
Patients with end stage kidney disease are subject to an extraordinarily high risk of 
cardiovascular disease-related death; sudden cardiac death, the most common cause of death 
for patients with end stage kidney disease treated with hemodialysis, occurs at a rate 30 
times greater than the general population.1 Among the many risk exposures that are 
prevalent in patients receiving hemodialysis, factors related to disordered mineral 
metabolism such as hyperphosphatemia, hypercalcemia, and secondary hyperparathyroidism 
have been associated with increased likelihood of cardiovascular events in observational 
studies. 2 Putative mechanisms include adverse hemodynamic events and alterations in 
vascular compliance due to arterial calcification. 3, 4
Processes that pertain to the dialytic removal of calcium have been reported to prompt 
hypotension, cardiac arrhythmias, and an increased risk of sudden death, most likely through 
disturbances in electrical conduction in the heart due to decreases in blood calcium 
concentration. 5–7 Prior studies indicate that the risk of sudden cardiac arrest in the 
immediate peri-dialytic period is two-fold higher among patients managed with dialysate 
calcium concentrations <2.5 mEq/L (<1.25 mmol/L). 7 Moreover, the likelihood of sudden 
cardiac arrest increased proportionally as a function of the difference in calcium 
concentration between serum and dialysate, a relationship that was more pronounced as the 
dialysate calcium level was reduced.
The calcimimetic agent cinacalcet (Sensipar®/ Mimpara®) treats secondary hyperthyroidism 
by inhibiting parathyroid hormone (PTH) secretion and lowering serum calcium. The 
randomized, placebo-controlled Evaluation of Cinacalcet Hydrochloride Therapy to Lower 
Cardiovascular Events (EVOLVE) trial examined the effect of cinacalcet on death and 
cardiovascular events among hemodialysis patients with moderate-to-severe secondary 
hyperparathyroidism. Overall, cinacalcet did not significantly reduce the risk of death or 
major cardiovascular events compared to placebo (relative hazard in patients randomized to 
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cinacalcet group versus placebo group=0.93; 95% confidence interval, 0.85 to 1.02; p=0.11). 
Analysis adjusted for baseline characteristics showed a nominally significant reduction in 
risk.8 Because of the calcium-lowering effect of cinacalcet, and prior observations of 
cardiovascular risk associated with dialysate calcium, we sought to determine whether 
variations in baseline dialysate calcium concentration or the serum-dialysate calcium 
gradient modified the effects of cinacalcet on death and cardiovascular events among 
participants in the EVOLVE trial.
 METHODS
 Study Population and Design
In the EVOLVE trial, 3883 patients with secondary hyperparathyroidism receiving 
hemodialysis were randomized 1:1 to either cinacalcet or placebo. All patients received 
conventional therapies for chronic kidney disease mineral bone disorder (CKD-MBD) (i.e., 
instructions for dietary phosphorus restriction, phosphate binders, and vitamin D sterols).9 
Eligible participants were on hemodialysis three times per week with plasma PTH 
concentrations ≥ 300 pg/mL (31.8 pmol/L), serum calcium phosphate product ≥ 45 mg2/dL2 
(3.63 mmol2/L2), and serum calcium ≥ 8.4 mg/dL (2.1 mmol/L). The dose of study drug was 
titrated once every 4 weeks during the first 20 weeks and every 8 weeks during the 
subsequent follow-up period (from a starting dose of 30 mg to a maximum dose of 180 mg 
daily), depending on blood levels of PTH and calcium. The dialysis prescription (including 
dialysate electrolyte composition) and all other medications including phosphate binders, 
vitamin D sterols and calcium supplements were administered at the discretion of treating 
clinicians. Information on the dialysate prescription was collected at approximately 6-month 
intervals. The trial was led by an academic Executive Committee and sponsored by Amgen, 
Inc. Institutional Review Board or Ethics Committee approval was obtained at all 
participating sites; all patients gave informed consent.
 Study Endpoints
For the purpose of these analyses, we examined whether baseline dialysate calcium or the 
serum–dialysate calcium gradient (determined from the difference between the last recorded 
dialysate and pre-dialysis serum calcium concentrations) modified the effect of cinacalcet on 
the following three endpoints: 1) primary composite endpoint (time to all-cause death or first 
non-fatal myocardial infarction, hospitalization for unstable angina, heart failure or 
peripheral vascular event); 2) cardiovascular death (one of the key secondary endpoints); and 
3) sudden death. All cardiovascular endpoints were adjudicated by an independent Clinical 
Events Committee.
 Calculation of corrected serum calcium and serum-dialysate calcium gradients
For patients with albumin levels less than 4 mg/dL, serum calcium was reported as a 
corrected value by the central laboratory using the following equation: corrected calcium in 
mg/dL= (0.8 × (4 − serum albumin in mg/dL) + serum calcium). Serum calcium 
concentrations were converted from mg/dL to mEq/L by multiplying by 0.5. For this study, 
we defined the serum-dialysate calcium gradient as the difference between total corrected 
Pun et al. Page 3
Hemodial Int. Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
serum calcium concentration minus dialysate calcium concentration in mEq/L, measured at 
baseline.
 Statistical Analysis
We used generalized estimating equations to test the difference between the treatment arms 
in dialysate calcium prescription, serum calcium and serum-dialysate calcium gradient over 
time. We used multivariable proportional hazards (Cox) regression analysis to evaluate 
associations among baseline dialysate calcium concentrations or the serum–dialysate 
calcium gradients and outcomes (primary composite endpoint, cardiovascular death, and 
sudden death). We adjusted for baseline characteristics, including age, sex, race (white, 
black, other), geographic region, history of diabetes mellitus, and history of cardiovascular 
diseases, among other factors. Covariates were selected by a process of backward 
elimination from a list of biologically plausible baseline covariates that were also associated 
with endpoints in univariate analyses. We tested for effect modification by baseline dialysate 
calcium concentration and the serum–dialysate calcium gradient using multiplicative 
interaction terms. The effect of cinacalcet versus placebo was evaluated using the intention-
to-treat principle. All inference tests were performed without adjusting for multiple 
comparisons. As the effects of randomization to cinacalcet versus placebo on the primary 
composite endpoint did not reach statistical significance in an unadjusted log-rank test, 
subsequent comparisons yielding 2-tailed p-values <0.05 were deemed nominally 
significant. We conducted all statistical analyses at Stanford University using SAS 9.3 (Cary, 
NC, USA).
 RESULTS
Table 1 shows baseline characteristics of patients in EVOLVE treated with different 
dialysate calcium concentrations assigned to receive either cinacalcet or placebo. 
Differences between placebo and cinacalcet groups have been previously described.10 
Nearly half of all study participants were prescribed dialysate calcium concentrations of 2.5 
mEq/L, and the use of different dialysate calcium concentrations at baseline (categorized as 
<2.5, 2.5 or ≥ 2.5 mEq/L) did not differ between the cinacalcet and placebo groups. Patients 
treated with lower dialysate calcium were older and were more likely to be black and 
female. Among patients prescribed lower dialysate calcium, the prevalence of baseline 
vitamin D sterol use was higher, the use of calcium-based phosphate binders was lower, and 
the proportion of patients with a history of cardiac disease (heart failure, coronary artery 
disease and arrhythmia) was higher.
 Regional Differences in Dialysate Calcium Prescription
Table 2 shows baseline prescribing patterns of dialysate calcium by geographic region. 
There were marked differences, with a predominance of higher dialysate calcium usage in 
Europe and Latin America (high calcium dialysate >2.5 mEq/L used in 59% of patients from 
the combined regions), and a predominance of lower dialysate calcium usage in the United 
States (≤2.5 mEq/L used in 96% of patients; <2.5 mEq/L used in 21% of patients).
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 Changes in serum and dialysate calcium over time
There was a small increase in prescriptions for dialysate calcium >2.5 mEq/L over the 
course of the trial and a decline in the use of 2.5 mEq/L prescriptions. There were no 
significant differences in dialysate calcium prescribing patterns between treatment groups 
(Figure 1).
Median serum calcium concentrations did not differ between treatment groups at baseline, 
but serum calcium declined in patients randomized to cinacalcet, with the separation most 
pronounced at 52 weeks (9.3 mg/dl in the cinacalcet group, 9.9 mg/dl in the placebo group). 
Concordant with changes in serum calcium, the serum–dialysate calcium gradient also 
showed separation over time between treatment groups; the group assigned to cinacalcet had 
a fall in the serum–dialysate gradient as compared to the group assigned to placebo and the 
difference was maximal at 52 weeks and narrowed over time (Figure 2).
As reported previously, there was a slight decrease in the use of vitamin D sterols and an 
increase in the use of calcium-containing phosphate binders over time in the group 
randomized to cinacalcet. 8
 Baseline dialysate calcium, serum–dialysate calcium gradient and cardiovascular 
endpoints
Nine hundred thirty-eight (48.2%) of the group randomized to cinacalcet experienced the 
primary composite endpoint, compared to 952 (49.2%) in the placebo group. There were 
377 (19.4%) cardiovascular deaths and 109 (5.6%) sudden deaths in the cinacalcet arm 
compared to 391 (20.2%) cardiovascular deaths and 115 (5.9%) sudden deaths in the 
placebo arm. Associations among dialysate calcium concentration, serum-dialysate calcium 
gradients and study endpoints were examined. In unadjusted analyses, the risk of all 
outcomes was significantly increased among patients exposed to higher serum-dialysate 
calcium gradients, and the risk of the primary composite outcome was increased among 
patients exposed to low calcium dialysate <2.5 mEq/L. However, after adjustment for other 
baseline factors and treatment assignment, no associations among these factors and the 
primary composite endpoint, cardiovascular death, and sudden death were observed. (Table 
3)
 Effect modification by the serum–dialysate calcium gradient and the dialysate calcium 
concentration
Figures 3 and 4 shows the relative hazard of the primary composite outcome, cardiovascular 
death and sudden death comparing cinacalcet versus placebo across the quintiles of baseline 
serum–dialysate calcium gradient and baseline dialysate calcium prescription. There was no 
significant modification of the effect of cinacalcet on outcomes by the serum–dialysate 
calcium gradient (Figure 3). Examination of outcomes by dialysate calcium concentration is 
shown in Figure 4; there was no significant interaction (effect modification) by dialysate 
calcium strata.
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 DISCUSSION
In this study, we examined the prescription of dialysate calcium in a large multi-national 
randomized clinical trial comparing the calcimimetic cinacalcet and placebo along with 
conventional therapy for CKD-MBD. There were large regional differences in baseline 
dialysate calcium prescription. Despite a significant decline in serum calcium concentration 
among patients randomized to cinacalcet, relatively few patients had their dialysate calcium 
prescriptions changed over the course of the trial. The baseline dialysate calcium 
concentration and baseline serum–dialysate calcium gradient were not associated with the 
primary composite endpoint (death or first non-fatal myocardial infarction, hospitalization 
for unstable angina, heart failure or peripheral vascular event), cardiovascular death or 
sudden death after adjustment for covariates. Moreover, we found that neither dialysate 
calcium nor the serum-dialysate calcium gradient modified the effect of cinacalcet on 
outcomes.
The ideal dialysate calcium concentration has prompted a long-standing debate, particularly 
with the development of newer agents used in the treatment of chronic kidney disease 
mineral bone disease (CKD-MBD), including non-calcium-containing phosphate binders 
and the calcimimetic cinacalcet. It has been evident for decades that persons with 
longstanding and/or severe kidney disease are likely to develop complications related to 
calcification of soft tissues. Many tissues can become calcified in patients with CKD, but 
involvement of heart valves and arteries has been the most extensively studied. Since 
dialysate calcium concentration is one of the key factors determining dialysis and total body 
calcium balance, current Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines 
recommend that dialysate calcium concentration be carefully titrated in an effort to maintain 
neutral or negative calcium balance and to prevent vascular calcification.11 However, others 
including the Kidney Disease: Improving Global Outcomes (KDIGO) Mineral and Bone 
Disorder workgroup have expressed concern that exposure to low calcium dialysate has been 
associated with secondary hyperparathyroidism, intradialytic hypotension, and cardiac 
arrhythmias including sudden cardiac arrest, leading to uncertainty on the “ideal” dialysate 
calcium concentration and whether or not individualization of dialysate calcium provides 
significant overall benefits.12, 13
This lack of consensus on the ideal dialysate calcium is manifest by substantial variation in 
prescribing habits around the world. More than 50% of all baseline prescriptions in 
EVOLVE were for a dialysate calcium >2.5 mEq/L in Europe, Australia, Latin America and 
Russia (>80% of all prescriptions in Australia and Russia), whereas in North America, a 
dialysate calcium concentration of 2.5 mEq/L was most frequently prescribed (>75% of all 
prescriptions) with more than one in five patients prescribed dialysate calcium 
concentrations <2.5 mEq/L. The use of lower dialysate calcium in North America and higher 
dialysate calcium in other regions confirms earlier reports; reasons for these regional 
preferences are uncertain, but may be related to frequent use of high-dose vitamin D sterols 
in the United States.14–16
The availability of cinacalcet to manage secondary hyperparathyroidism offers new 
opportunities and challenges in the management of calcium homeostasis. Cinacalcet inhibits 
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parathyroid hormone release, resulting in a fall in serum calcium. The decline in serum 
calcium can influence clinical decision-making with respect to dialysate calcium 
concentration. On one hand, for patients who begin with normal or low serum calcium 
concentrations, declining serum calcium concentrations might prompt an increase in 
dialysate calcium. On the other hand, for patients with hypercalcemia, cinacalcet may 
provide a means to lower serum calcium concentrations without lowering dialysate calcium. 
In the EVOLVE trial, treating physicians were not blinded to serum calcium concentrations 
and were allowed to alter dialysis prescriptions at their discretion. Although the median 
serum calcium decreased by nearly 1 mg/dL in the cinacalcet arm, the dialysate calcium 
prescription was rarely changed, with no discernible difference in prescription changes for 
dialysate calcium between the cinacalcet and placebo groups. This may reflect a resistance 
to modification of dialysate calcium in favor of other means of altering serum calcium 
concentrations (changes in oral calcium supplementation or vitamin D sterols). While we 
observed an increase in the use of calcium-containing phosphate binder use in the cinacalcet 
arm, the effects on serum calcium concentration may have been offset by a concomitant 
decrease in vitamin D sterol use. It is also possible that lack of changes to dialysate calcium 
resulted from clinical inertia or uncertainty regarding the clinical significance of changes in 
serum calcium. Indeed, although both hypo- and hypercalcemia have been associated with 
adverse outcomes in observational studies, the optimal serum calcium concentration has not 
been determined prospectively.
Several studies have shown associations among intradialytic fall in serum calcium, low 
calcium dialysate, and electrocardiographic QT prolongation, a marker of arrhythmic 
risk. 6, 17 In a case-control study of prevalent patients receiving hemodialysis, dialysate 
calcium <2.5 mEq was associated with a doubling in the odds of peri-dialytic in-facility 
sudden cardiac arrest.7 In addition, a larger calcium “gradient,” determined by the difference 
between the most recent serum and the prescribed dialysate calcium concentrations, was also 
associated with an increased risk of in-facility cardiac arrest in this study (odds ratio 1.40, 
95% CI 1.10 to 1.80 per 1 mEq/L increase). A recent study examining the outcomes in 
dialysis units that lowered default dialysate calcium from 2.5 mEq/L to less than 2.5 mEq 
also suggested an increase in heart failure hospitalization and intradialytic hypotension.18 
While our unadjusted analyses showed a similar significant adverse association between low 
dialysate calcium and high calcium gradients with cardiovascular events, the association did 
not persist after adjustment for covariates. This could suggest that effect sizes observed in 
previous studies might be reduced after further adjustment for residual confounding.
We found that neither the dialysate calcium concentration nor the dialysate–serum calcium 
gradient significantly influenced the effects of cinacalcet. Additionally, although the decline 
in serum calcium concentration was limited to some extent by increased prescription of 
calcium-containing phosphate binders, it is important to note that the results herein suggest 
that the hypocalcemic effects of cinacalcet do not increase the risk of sudden death. If there 
is a benefit of cinacalcet on sudden death or other cardiovascular endpoints, these effects 
may be independent of effects on serum calcium, perhaps reflecting salutary effects of PTH 
lowering.
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Several important limitations should be considered. First, we did not have data on serum 
ionized calcium. Ionized calcium would be a better measure of the diffusible serum calcium-
to-dialysate gradient and overall dialyzer calcium flux, since only unbound calcium is 
dialyzable. Nevertheless, there is evidence that bound calcium dissociates rapidly, making 
total serum calcium the effective driving force for diffusion19 and thus, the difference 
between total serum calcium and dialysate calcium levels would be expected to be 
proportional to the diffusible calcium gradient. Second, in order to avoid indication bias and 
confounding associated with changes in serum and dialysate calcium, we considered only 
baseline concentrations when testing for effect modification. As such, the exposure of some 
patients may have been misclassified, if during the majority of their months on study they 
were treated with a different dialysate calcium concentration relative to baseline. However, 
since relatively few patients had their dialysate calcium concentrations changed, substantial 
misclassification is unlikely. Third, the power of the trial was limited by extensive non-
adherence to the randomized assignment as well as by co-interventions that lowered PTH 
(parathyroidectomy, kidney transplantation and use of commercial cinacalcet). In turn, the 
power to detect a meaningful interaction (effect modification) is reduced. While we have no 
evidence of effect modification by either dialysate calcium or the serum–dialysate calcium 
gradient, it is possible that one exists; yet we were unable to detect it. Finally, the results 
could have been influenced by co-interventions that were not carefully tracked (e.g., use of 
over-the-counter calcium supplements and/or oral vitamin D sterols, changes in dietary 
calcium).
In summary, this study demonstrates major regional differences in the prescription of 
dialysate calcium. We observed no association between dialysate calcium or the serum–
dialysate calcium gradient and the primary composite endpoint, cardiovascular death, or 
sudden death. We observed relative hypocalcemia induced by cinacalcet, with infrequent up-
titration of the dialysate calcium. Despite relative hypocalcemia associated with cinacalcet, 
the risk of sudden cardiac death was not increased. Finally, we found that the effects of 
cinacalcet were not modified by the dialysate calcium or the serum–dialysate calcium 
gradient, although the power to detect such an interaction was low. There is continued 
uncertainty with respect to the optimal dialysate calcium concentration, with or without 
conventional and newer therapeutics for CKD-MBD.
 Acknowledgments
Sources of Funding: The EVOLVE trial was supported by Amgen. SA and GMC received grant funding from 
Amgen to conduct secondary data analysis using EVOLVE data. PHP was also supported by grant 
(1K23DK098281-01) from the National Institute of Diabetes and Digestive and Kidney Diseases.
The EVOLVE trial was funded by Amgen. This work was also supported by grant funding (1K23DK098281-01) 
from the National Institute of Diabetes and Digestive and Kidney Diseases (Dr. Pun).
References
1. Herzog CA, Asinger RW, Berger AK, Charytan DM, Diez J, Hart RG, et al. Cardiovascular disease 
in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes 
(KDIGO). Kidney Int. 2011; 80(6):572–586. [PubMed: 21750584] 
Pun et al. Page 8
Hemodial Int. Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
2. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, 
mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15(8):2208–2218. 
[PubMed: 15284307] 
3. Suzuki T, Yonemura K, Maruyama Y, Takahashi T, Takita T, Furuhashi M, Hishida A. Impact of 
serum parathyroid hormone concentration and its regulatory factors on arterial stiffness in patients 
undergoing maintenance hemodialysis. Blood Purif. 2004; 22(3):293–297. [PubMed: 15166491] 
4. London GM, Marchais SJ, Guerin AP, Metivier F. Arteriosclerosis, vascular calcifications and 
cardiovascular disease in uremia. Current opinion in nephrology and hypertension. 2005; 14(6):
525–531. [PubMed: 16205470] 
5. van der Sande FM, Cheriex EC, van Kuijk WH, Leunissen KM. Effect of dialysate calcium 
concentrations on intradialytic blood pressure course in cardiac-compromised patients. Am J 
Kidney Dis. 1998; 32(1):125–131. [PubMed: 9669433] 
6. Severi S, Grandi E, Pes C, Badiali F, Grandi F, Santoro A. Calcium and potassium changes during 
haemodialysis alter ventricular repolarization duration: in vivo and in silico analysis. Nephrol Dial 
Transplant. 2008; 23(4):1378–1386. [PubMed: 18045821] 
7. Pun PH, Horton JR, Middleton JP. Dialysate calcium concentration and the risk of sudden cardiac 
arrest in hemodialysis patients. Clinical journal of the American Society of Nephrology : CJASN. 
2013; 8(5):797–803. [PubMed: 23371957] 
8. Investigators ET, Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, et al. Effect of 
cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012; 367(26):
2482–2494. [PubMed: 23121374] 
9. Chertow GM, Pupim LB, Block GA, Correa-Rotter R, Drueke TB, Floege J, et al. Evaluation of 
Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. 
Clin J Am Soc Nephrol. 2007; 2(5):898–905. [PubMed: 17702710] 
10. Chertow GM, Correa-Rotter R, Block GA, Drueke TB, Floege J, Goodman WG, et al. Baseline 
characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower 
Cardiovascular Events (EVOLVE) trial. Nephrol Dial Transplant. 2012; 27(7):2872–2879. 
[PubMed: 22529163] 
11. Uhlig K, Berns JS, Kestenbaum B, Kumar R, Leonard MB, Martin KJ, et al. KDOQI US 
commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and 
Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis. 2010; 55(5):773–
799. [PubMed: 20363541] 
12. Messa P, Sherman RA. Should Dialysate Calcium be Individualized? Semin Dial. 2014; 27(1):4–7. 
[PubMed: 24400799] 
13. Kidney Disease: Improving Global Outcomes CKDMBDWG. KDIGO clinical practice guideline 
for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and 
Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009; (113):S1–130.
14. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, et al. Predictors and 
consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. 
Kidney Int. 2005; 67(3):1179–1187. [PubMed: 15698460] 
15. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al. ACC/AHA/ESC 
2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of 
Sudden Cardiac Death: a report of the American College of Cardiology/American Heart 
Association Task Force and the European Society of Cardiology Committee for Practice 
Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular 
Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the 
European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006; 
114(10):e385–484. [PubMed: 16935995] 
16. Tentori F, Albert JM, Young EW, Blayney MJ, Robinson BM, Pisoni RL, et al. The survival 
advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis 
Outcomes and Practice Patterns Study. Nephrol Dial Transplant. 2009; 24(3):963–972. [PubMed: 
19028748] 
17. Genovesi S, Dossi C, Vigano MR, Galbiati E, Prolo F, Stella A, Stramba-Badiale M. Electrolyte 
concentration during haemodialysis and QT interval prolongation in uraemic patients. Europace. 
2008; 10(6):771–777. [PubMed: 18287086] 
Pun et al. Page 9
Hemodial Int. Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
18. Brunelli SM, Sibbel S, Do TP, Cooper K, Bradbury BD. Facility Dialysate Calcium Practices and 
Clinical Outcomes Among Patients Receiving Hemodialysis: A Retrospective Observational 
Study. Am J Kidney Dis. 2015; 66(4):655–665. [PubMed: 26015274] 
19. Gotch F, Levin NW, Kotanko P. Calcium balance in dialysis is best managed by adjusting dialysate 
calcium guided by kinetic modeling of the interrelationship between calcium intake, dose of 
vitamin D analogues and the dialysate calcium concentration. Blood Purif. 2010; 29(2):163–176. 
[PubMed: 20093823] 
Pun et al. Page 10
Hemodial Int. Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Dialysate Calcium Concentration over the course of the trial in cinacalcet (Panel A) and 
placebo (Panel B) treated groups.
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Figure 2. 
Median Serum-Dialysate Gradient over time (bars represent the range between 10th and 
90th percentiles)
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Figure 3. 
Forest plots of covariate-adjusted relative hazard and 95% CI for the primary composite 
outcome, cardiovascular mortality and sudden cardiac death by baseline serum-to-dialysate 
calcium gradient quintile groups (Lowest quintile <1.75 mEq/L; Low middle quintile 1.75–
2.10 mEq/L; middle quintile = 2.11–2.35 mEq/L; higher middle quintile = 2.36–2.65 
mEq/L; highest quintile >2.65 mEq/L). Interactions with the continuous baseline calcium 
gradient variable were p=0.663 for the primary composite endpoint, p=0.826 for the 
cardiovascular mortality endpoint and p=0.771 for the sudden death endpoint.
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Figure 4. 
Forest plots of covariate-adjusted HR and 95% CI for the primary composite outcome, 
cardiovascular mortality and sudden cardiac death by baseline dialysate calcium 
prescription. Interactions with the dialysate calcium variable were p=0.117 for the primary 
composite endpoint, p=0.205 for the cardiovascular mortality endpoint, and p=0.434 for the 
sudden death endpoint.
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